Maurício Palmeira de Souza

Prof. Maurício Palmeira de Souza

UNESP - São Paulo State University

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Carbohydrate Polymers
Verified
Journal Article
Closed access
LFLeonardo Miziara Barboza Ferreira
Leonardo Miziara Barboza Ferreira
ASAline M. dos Santos
Aline M. dos Santos
FBFernanda Isadora Boni
Fernanda Isadora Boni
KSKaio Pini Santos
Kaio Pini Santos
LRLeda M. Gorla Robusti
Leda M. Gorla Robusti
MGMaria Palmira Daflon Gremiao
Maria Palmira Daflon Gremiao

1 September 2020 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
MSMaurício Palmeira de Souza
Maurício Palmeira de Souza
RSRafael Miguel Sábio
Rafael Miguel Sábio
TRTais de Cassia Ribeiro
Tais de Cassia Ribeiro
ASAline Martins dos Santos
Aline Martins dos Santos
AMAndréia Bagliotti Meneguin
Andréia Bagliotti Meneguin
Marlus ChorilliMarlus Chorilli
Marlus Chorilli

16 March 2021 in Critical Reviews in Microbiology
Verified
Journal Article
Closed access
MSMaurício Palmeira de Souza
Maurício Palmeira de Souza
BCBruna Almeida Furquim de Camargo
Bruna Almeida Furquim de Camargo
LSLarissa Spósito
Larissa Spósito
GFGiovanna Capaldi Fortunato
Giovanna Capaldi Fortunato
GCGabriela Corrêa Carvalho
Gabriela Corrêa Carvalho
Marlus ChorilliMarlus Chorilli
Marlus Chorilli
Due to the high adaptability of Helicobacter pylori and the low targeting specificity of the drugs normally used in pharmacological therapy, the strains are becoming increasingly resistant to these drugs, making it difficult to eradicate the infection. Thus, the search for new therapeutic approaches has been considered urgent. The incorporation of drugs in advanced drug delivery systems, such as nano and microparticles, would allow the improvement of the retention time in the stomach and the prolongation of drug release rates at the target site. Because of this, the present review article aims to highlight the use of micro and nanoparticles as important technological tools for the treatment of H. pylori infections, focussing on the main nanotechnological systems, including nanostructured lipid carriers, liposomes, nanoemulsion, metallic nanoparticles, and polymeric nanoparticles, as well as microtechnological systems such as gastroretentive dosage forms, among them mucoadhesive, magnetic and floating systems were highlighted.

19 September 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Andreía MeneguinAndreía Meneguin
Andreía Meneguin
RSRafael Miguel Sábio
Rafael Miguel Sábio
MSMaurício Palmeira de Souza
Maurício Palmeira de Souza
RFRichard Perosa Fernandes
Richard Perosa Fernandes
AOAnselmo Gomes de Oliveira
Anselmo Gomes de Oliveira
Marlus ChorilliMarlus Chorilli
Marlus Chorilli
Cellulose nanofibers (CNF) were employed as the nanoreinforcement of a retrograded starch/pectin (RS/P) excipient to optimize its colon-specific properties. Although starch retrogradation ranged from 32 to 73%, CNF addition discretely disfavored the RS yield. This result agrees with the finding that in situ CNF reduces the presence of the RS crystallinity pattern. A thermal analysis revealed that the contribution of pectin improves the thermal stability of the RS/CNF mixture. Through a complete factorial design, it was possible to optimize the spray-drying conditions to obtain powders with high yield (57%) and low moisture content (1.2%). The powders observed by Field Emission Gum Scanning Electron Microscopy (FEG-SEM) had 1–10 µm and a circular shape. The developed methodology allowed us to obtain 5-aminosalicilic acid-loaded microparticles with high encapsulation efficiency (16–98%) and drug loading (1.97–26.63%). The presence of CNF in RS/P samples was responsible for decreasing the burst effect of release in simulated gastric and duodenal media, allowing the greatest mass of drug to be targeted to the colon. Considering that spray-drying is a scalable process, widely used by the pharmaceutical industry, the results obtained indicate the potential of these microparticles as raw material for obtaining other dosage forms to deliver 5-ASA to the distal parts of gastrointestinal tract, affected by inflammatory bowel disease.

1 June 2020 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
ASAline Martins dos Santos
Aline Martins dos Santos
AMAndréia Bagliotti Meneguin
Andréia Bagliotti Meneguin
BFBruno Fonseca-Santos
Bruno Fonseca-Santos
MSMaurício Palmeira de Souza
Maurício Palmeira de Souza
LFLeonardo Miziara Barboza Ferreira
Leonardo Miziara Barboza Ferreira
MGMaria Palmira Daflon Gremião
Maria Palmira Daflon Gremião

7 April 2021 in Journal of Drug Targeting
Verified
Journal Article
Closed access
LSLarissa Spósito
Larissa Spósito
GFGiovanna Capaldi Fortunato
Giovanna Capaldi Fortunato
BCBruna Almeida Furquim de Camargo
Bruna Almeida Furquim de Camargo
MRMatheus Aparecidos Dos Santos Ramos
Matheus Aparecidos Dos Santos Ramos
MSMaurício Palmeira de Souza
Maurício Palmeira de Souza
Marlus ChorilliMarlus Chorilli
Marlus Chorilli
Peptic ulcer disease (PUD) is a common condition that is induced by acid and pepsin causing lesions in the mucosa of the duodenum and stomach. The pathogenesis of PUD is a many-sided scenario, which involves an imbalance between protective factors, such as prostaglandins, blood flow, and cell renewal, and aggressive ones, like alcohol abuse, smoking, Helicobacter pylori colonization, and the use of non-steroidal anti-inflammatory drugs. The standard oral treatment is well established; however, several problems can decrease the success of this therapy, such as drug degradation in the gastric environment, low oral bioavailability, and lack of vectorization to the target site. In this way, the use of strategies to improve the effectiveness of these conventional drugs becomes interesting. Currently, the use of drug delivery systems is being explored as an option to improve the drug therapy limitations, such as antimicrobial resistance, low bioavailability, molecule degradation in an acid environment, and low concentration of the drug at the site of action. This article provides a review of oral drug delivery systems looking for improving the treatment of PUD.